Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, and haemophilus B conjugate vaccine and guidance for use in infants and children

디프테리아 및 파상풍 톡소이드와 세포외 백일해, 흡착된 비활성화 폴리오바이러스, 그리고 헤모필루스 B 결합 백신의 면허 및 영유아와 어린이 사용에 대한 지침

Published on
Journal: Morbidity and Mortality Weekly Report
[저자] Centers for Disease Control and Prevention (CDC)
[Category] 백일해, 파상풍,
Pubmed URL    DOI URL    
[Source] pubmed

On June 20, 2008 the Food and Drug Administration (FDA) licensed a combined diphtheria and tetanus toxoids and acellular pertussis adsorbed (DTaP), inactivated poliovirus vaccine (IPV), and Haemophilus influenzae type b conjugate (tetanus toxoid [TT] conjugate) vaccine, DTaP-IPV/Hib (Pentacel, Sanofi Pasteur, Swiftwater, Pennsylvania), for use as a four-dose series in infants and children at ages 2, 4, 6, and 15-18 months. This report summarizes the indications for Pentacel and provides guidance from the Advisory Committee on Immunization Practices (ACIP) for its use.

All Keywords